Karim Mikhail Promises Stability at FDA Biologics Center After 1 Stormy Leadership Chapter
Updated
Updated · STAT · Jul 15
Karim Mikhail Promises Stability at FDA Biologics Center After 1 Stormy Leadership Chapter
1 articles · Updated · STAT · Jul 15
Summary
Karim Mikhail told FDA biologics staff in a June town hall that he was “normal” and understood what employees were going through, signaling a reset as acting director.
The message landed because Mikhail has taken over the Center for Biologics Evaluation and Research after Vinay Prasad, whose tenure staff viewed as unusually turbulent and outside the norm.
CBER oversees biologics regulation, so Mikhail’s early emphasis on steadiness points to an effort to calm internal disruption and restore routine leadership at a key FDA center.